급성 통증 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the acute pain market size is projected to expand from USD 13.53 billion in 2025 and USD 14.13 billion in 2026 to USD 18.29 billion by 2031, registering a CAGR of 5.30% between 2026 to 2031.

This report is Segmented by Drug Class (NSAIDs, Acetaminophen, Opioids, Local Anesthetics, Adjunctive Therapies), Pain Type (Postoperative, Trauma, Dental, Musculoskeletal & Sports, Acute Medical), Route of Administration (Oral, Injectable, Topical, Others), Distribution Channel (Hospital, Retail, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, MEA, South America)

Global Acute Pain Market Trends and Insights

Rising Surgical And Procedural Volumes

Surgical and procedural volumes continue to expand across developed and emerging healthcare systems. U.S. total hip arthroplasty volume rose 177%, while total knee arthroplasty volume rose 156% during the 2 decades to 2019, and procedure backlogs continued to support demand after the pandemic period. Higher-acuity procedures are moving into ambulatory settings, which increases the need for effective pain control after same-day discharge. Patients recovering at home cannot rely on extended inpatient monitoring, so providers need longer-acting and practical regimens. The 2026 American Society of Anesthesiologists guidelines recommend regional analgesia and surgical-site infiltration within multimodal perioperative care. This guidance supports broader use and more consistent protocol design across the acute pain market and across the acute pain treatment pathway.

Opioid-Sparing Treatment Adoption

The move away from opioid-centered treatment has become tied to clinical practice and payment requirements. CMS Measure 477 encourages clinicians to document multimodal pain management during the perioperative period. A 2026 systematic review found that adding a second multimodal component reduced 24-hour opioid use by 5.2 mg oral morphine equivalents and reduced pain scores at 4 hours. This evidence makes the case for protocols that combine established analgesics with regional or local options. The U.S. Centers for Disease Control and Preventionrecommends the lowest effective opioid dose for the shortest necessary duration for acute pain. As opioid use falls, the acute pain market can still gain value because replacement therapies often carry higher prices than generic opioids, making reimbursement design important across the acute pain market.

Opioid Safety Scrutiny And Prescribing Restrictions

Tighter opioid controls create a mixed outcome for the acute pain market. The CDC guidance limits duration and dose, while state policies can cap the supply prescribed for acute pain. These measures reduce the role of opioids but do not automatically move every patient to premium non-opioid products. Many providers and payers still rely on lower-cost NSAIDs and acetaminophen when budgets are limited. Research cited in the supplied material reported that 50% of tertiary-care patients had inadequate pain relief, while more than 80% experienced moderate-to-severe postoperative pain within 2 weeks of discharge. The result can be fragmented treatment, with patients remaining undertreated while payers resist higher-cost alternatives.

Other drivers and restraints analyzed in the detailed report include:

1. Expansion Of Ambulatory And Same-Day Surgery
2. Innovation For Underserved Care Settings
3. High Cost Of Novel Non-Opioid Therapies

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

NSAIDs held 34.5% of revenue in 2025, making them the largest drug class in the acute pain market. Their position reflects broad use in postoperative, musculoskeletal, dental, and over-the-counter care. They are supported by long clinical experience and availability across hospital, retail, and digital channels. A 2025 study found that NSAIDs and dexamethasone reduced postoperative pain scores and opioid consumption more effectively than acetaminophen within multimodal regimens. That evidence can influence hospital committees that still treat acetaminophen as the default non-opioid option.

Local anesthetics are forecast to record the fastest growth at a 6.2% CAGR through 2031. Liposomal bupivacaine is used more often in orthopedic, reconstructive, and spine procedures. Pacira reported 7% year-over-year EXPAREL volume growth in the first quarter of 2026. Acetaminophen remains a widely used adjunct across age groups, while opioids remain necessary in high-severity postoperative and acute oncology settings. Gabapentinoids, ketamine, dexmedetomidine, and corticosteroids are increasingly used as components of combination protocols rather than as stand-alone choices.

Postoperative pain accounted for 31.8% of revenue in 2025, reflecting its role in nearly every surgical specialty. It is often the most treatment-intensive application because pain may continue after a patient leaves the facility. This creates demand across hospital and retail channels. Procedure-specific protocols also make postoperative care important for label development and hospital formulary decisions. The acute pain industry continues to depend on surgical applications because they combine predictable demand with closely managed treatment pathways. These applications remain central to the acute pain market.

Musculoskeletal and sports pain is projected to grow at a 6.8% CAGR through 2031. Participation in sports, workplace injuries, and emergency trauma care are extending use beyond planned surgical settings. Trauma and injury pain remains underpenetrated because emergency department treatment is often insufficient. The supplied research cited findings that 74% of emergency department patients still reported moderate-to-severe pain at discharge despite receiving medication. Dental pain remains a high-volume indication for OTC products, while renal colic, sickle cell crises, and migraines have their own treatment needs and specialist pathways.

Complete Report Scope:

• By Drug Class
  • Nonsteroidal Anti-Inflammatory Drugs
  • Acetaminophen and Paracetamol
  • Opioids
  • Local Anesthetics
  • Adjunctive Therapies
• By Pain Type and Clinical Application
  • Postoperative Pain
  • Trauma & Injury Pain
  • Dental Pain
  • Musculoskeletal & Sports Pain
  • Acute Medical Condition Pain
• By Route of Administration
  • Oral
  • Injectable and Parenteral
  • Topical and Transdermal
  • Other Routes (Inhaled, rectal, etc)
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies and Drug Stores
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 42.1% of global revenue in 2025, giving the region the largest acute pain market share. The region benefits from high procedure volumes, established hospital purchasing systems, and early adoption of multimodal protocols. Separate Medicare Part B payment for qualifying non-opioid pain drugs began in January 2025 and reduced a financial barrier in hospital outpatient departments and ambulatory surgery centers. Pacira announced in July 2026 that UnitedHealthcare provides separate reimbursement for EXPAREL across outpatient settings. Canada and Mexico add volume, but uptake of novel branded non-opioids remains more limited than in the United States.

Europe contributes meaningful demand through Germany, the United Kingdom, France, Italy, and Spain. National assessment and reimbursement processes can delay uptake of new analgesics even when clinical evidence is available. This environment favors established NSAIDs and acetaminophen until new therapies complete local reviews. Regional analgesia and multimodal care are increasingly consistent with European enhanced recovery practice. The Middle East and Africa have a two-tier profile, with Gulf Cooperation Council countries more able to adopt premium therapies while many sub-Saharan markets rely on generic medicines.

Asia-Pacific is projected to grow at a 6.3% CAGR through 2031, the fastest regional rate in the acute pain market. China and India are the main growth engines because of expanding healthcare infrastructure, manufacturing capacity, and large patient populations. Japan's aging population supports demand for non-opioid pain treatment, although regulatory reviews can slow new product access. Pacira entered an agreement with LG Chem in January 2026 to pursue EXPAREL commercialization in South Korea and Thailand. South America has rising demand for effective OTC products, but budget pressure and currency volatility limit adoption of premium therapies.

1. Vertex Pharmaceuticals
2. Pfizer
3. Johnson & Johnson
4. Viatris
5. Teva Pharmaceutical Industries
6. Bayer
7. Haleon plc
8. Kenvue Inc.
9. Reckitt Benckiser Group
10. Heron Therapeutics
11. Pacira BioSciences
12. Ocular Therapeutix, Inc.
13. Formosa Pharmaceuticals, Inc.
14. Medical Developments International Limited
15. Latigo Biotherapeutics
16. Neumentum, Inc.
17. Scilex Holding
18. Tris Pharma, Inc.
19. Sandoz Group AG
20. Sun Pharmaceuticals Industries

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Surgical and Procedural Volumes
  • 4.2.2 Opioid-Sparing Treatment Adoption
  • 4.2.3 Expansion of Ambulatory and Same-Day Surgery
  • 4.2.4 Acute-Pain Formulation Innovation in Underserved Care Settings
  • 4.2.5 Hospital Procurement Shift Toward Opioid-Free Recovery Pathways
  • 4.2.6 Growing Incidence of Trauma, Sports Injuries, and Emergency Care Cases
• 4.3 Market Restraints
  • 4.3.1 Opioid Safety Scrutiny and Prescribing Restrictions
  • 4.3.2 High Cost of Novel Non-Opioid Therapies
  • 4.3.3 Acute-Pain Trial Endpoint and Real-World Adoption Complexity
  • 4.3.4 Limited Reimbursement and Hospital Cost-Containment Pressures
• 4.4 Value and Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces
  • 4.7.1 Supplier Power
  • 4.7.2 Buyer Power
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry
  • 4.7.6 Porters Five Forces Analysis

5 MARKET SIZE AND GROWTH FORECASTS

• 5.1 By Drug Class
  • 5.1.1 Nonsteroidal Anti-Inflammatory Drugs
  • 5.1.2 Acetaminophen and Paracetamol
  • 5.1.3 Opioids
  • 5.1.4 Local Anesthetics
  • 5.1.5 Adjunctive Therapies
• 5.2 By Pain Type and Clinical Application
  • 5.2.1 Postoperative Pain
  • 5.2.2 Trauma & Injury Pain
  • 5.2.3 Dental Pain
  • 5.2.4 Musculoskeletal & Sports Pain
  • 5.2.5 Acute Medical Condition Pain
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Injectable and Parenteral
  • 5.3.3 Topical and Transdermal
  • 5.3.4 Other Routes (Inhaled, rectal, etc)
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies and Drug Stores
  • 5.4.3 Online Pharmacies
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Vertex Pharmaceuticals Incorporated
  • 6.3.2 Pfizer Inc.
  • 6.3.3 Johnson & Johnson
  • 6.3.4 Viatris Inc.
  • 6.3.5 Teva Pharmaceutical Industries Ltd.
  • 6.3.6 Bayer AG
  • 6.3.7 Haleon plc
  • 6.3.8 Kenvue Inc.
  • 6.3.9 Reckitt Benckiser Group plc
  • 6.3.10 Heron Therapeutics, Inc.
  • 6.3.11 Pacira BioSciences, Inc.
  • 6.3.12 Ocular Therapeutix, Inc.
  • 6.3.13 Formosa Pharmaceuticals, Inc.
  • 6.3.14 Medical Developments International Limited
  • 6.3.15 Latigo Biotherapeutics
  • 6.3.16 Neumentum, Inc.
  • 6.3.17 Scilex Holding Company
  • 6.3.18 Tris Pharma, Inc.
  • 6.3.19 Sandoz Group AG
  • 6.3.20 Sun Pharmaceutical Industries Limited

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment